STF Management LP Increases Stock Position in Amgen Inc. $AMGN

STF Management LP boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,243 shares of the medical research company’s stock after buying an additional 206 shares during the quarter. Amgen makes up 0.9% of STF Management LP’s holdings, making the stock its 25th biggest position. STF Management LP’s holdings in Amgen were worth $2,302,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Wealth Preservation Advisors LLC purchased a new position in shares of Amgen in the 1st quarter valued at about $25,000. CBIZ Investment Advisory Services LLC grew its holdings in Amgen by 1,214.3% in the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 85 shares during the period. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen in the second quarter valued at approximately $27,000. Activest Wealth Management raised its stake in shares of Amgen by 3,433.3% during the 1st quarter. Activest Wealth Management now owns 106 shares of the medical research company’s stock worth $33,000 after buying an additional 103 shares during the period. Finally, Quaker Wealth Management LLC lifted its position in shares of Amgen by 200.0% during the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after buying an additional 240 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on AMGN shares. Wells Fargo & Company increased their price objective on shares of Amgen from $280.00 to $300.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Bank of America raised their price target on shares of Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research note on Friday, September 26th. Guggenheim lifted their price objective on Amgen from $288.00 to $305.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. Citigroup increased their target price on Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a report on Wednesday, September 24th. Finally, The Goldman Sachs Group decreased their target price on Amgen from $405.00 to $400.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $311.74.

Amgen Price Performance

NASDAQ:AMGN opened at $323.66 on Tuesday. Amgen Inc. has a one year low of $253.30 and a one year high of $335.88. The stock has a market cap of $174.28 billion, a PE ratio of 26.46, a P/E/G ratio of 2.61 and a beta of 0.45. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The stock has a 50 day moving average price of $290.66 and a 200 day moving average price of $288.96.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.01 by $0.63. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The company had revenue of $9.56 billion during the quarter, compared to analysts’ expectations of $8.98 billion. During the same period in the prior year, the business earned $5.58 EPS. The firm’s quarterly revenue was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 12th. Investors of record on Friday, November 21st will be given a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 2.9%. The ex-dividend date is Friday, November 21st. Amgen’s dividend payout ratio (DPR) is presently 73.57%.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the business’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the transaction, the senior vice president directly owned 7,209 shares in the company, valued at $2,141,000.91. The trade was a 14.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.76% of the stock is owned by company insiders.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.